Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$331K Sell
2,278
-172
-7% -$23.8K 0.16% 66
2026
Q2
$315K Sell
2,450
-130
-5% -$15.2K 0.15% 71
2026
Q1
$310K Sell
2,580
-143
-5% -$16.5K 0.15% 64
2025
Q4
$287K Buy
2,723
+63
+2% +$5.91K 0.14% 64
2025
Q3
$223K Sell
2,660
-150
-5% -$12.4K 0.12% 72
2025
Q2
$222K Buy
2,810
+1,039
+59% +$82.6K 0.12% 71
2025
Q1
$159K Sell
1,771
-200
-10% -$18.7K 0.09% 79
2024
Q4
$196K Buy
1,971
+165
+9% +$17K 0.11% 65
2024
Q3
$205K Buy
1,806
+63
+4% +$7.48K 0.11% 65
2024
Q2
$216K Hold
1,743
– – 0.13% 64
2024
Q1
$230K Sell
1,743
-43
-2% -$5.3K 0.14% 62
2023
Q4
$195K Buy
+1,786
New +$185K 0.13% 71

Other funds holding MRK

Birchbrook's MRK Position: Q3 2026 in Review

Birchbrook reduced its Merck (MRK) stake by 7% in Q3 2026, selling an estimated $23.8K and leaving 2,278 shares worth $331K. The position accounts for 0.16% of the portfolio, ranked #66.

Birchbrook first reported a position in MRK in Q4 2023 and has held it in 12 quarters since. 1,788 funds tracked by Wall St. Rank hold MRK as of Q3 2026.

  • Birchbrook held 2,278 shares of Merck worth $331K as of Q3 2026.
  • Birchbrook sold 172 Merck shares in Q3 2026, an estimated $23.8K.
  • Merck made up 0.16% of Birchbrook's portfolio in Q3 2026, its #66 holding.
  • Birchbrook first reported a position in Merck in Q4 2023 and has held it in 12 quarters since.
  • 1,788 funds tracked by Wall St. Rank held Merck as of Q3 2026.

Based on Birchbrook's 13F filing for Q3 2026, filed 14 Oct 2026.